Muhammad j a shiddiky (23 resultados)

Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condición: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condición: Used. pp. 210 Index.

Condición: Used. pp. 210.

Condición: Used. pp. 210.

hardcover. Condición: Gut. 202 Seiten; 9781628080209.3 Gewicht in Gramm: 1.

Condición: New.

HRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.

Condición: New. Editor(s): Shiddiky, Muhammad J. A.; Wee, Eugene J. H.; Rauf, Sakandar; Trau, Matt. Num Pages: 227 pages. BIC Classification: MBGR. Category: (P) Professional & Vocational. Dimension: 258 x 183 x 18. Weight in Grams: 556. . 2013. 1st Edition. Hardcover. . . . .

Condición: As New. Unread book in perfect condition.

Hardcover. Condición: new. Hardcover. In recent years, thousands of cancer biomarkers have been discovered and described in scientific literature. The promise of personalised medicine, where diseases such as cancer are accurately diagnosed and treatments tailored specifically for individuals, is becoming a reality. Significant advances in biomarker-based research methodologies such as Next Generation Sequencing (NGS) are at the cusp of ushering in a new era of personal medicine. However, unlike the spectacular advances in research technologies for disease biomarker discovery, biomarker-based technologies that can effectively be used in the clinic (or point-of-care) to enable personalised medicine are still lacking. In this book, we feature a selection of emerging technologies which are aimed at enabling clinical applications of personalised medicine. Each of the eight chapters is written by a leading group at the intersection of microfluidics, biology, and nanotechnology.For instance, to accelerate a major bottleneck in the development of clinically useful protein diagnostics, we discuss the application of yeast-derived single chain Fragment variable (scFv) antibody-like molecules as a potential low cost alternative to traditional antibody-based diagnostics. Circulating tumour cells (CTCs) are an emerging class of cancer biomarkers and a potential resource for understanding cancer progression; we explore various strategies combining microfluidics with nanotechnology for capturing CTCs. The book includes an evaluation of some current and emerging technologies for detecting clinical DNA methylation, another potential cancer biomarker. As personalised medicine may involve tracking a patient's response to treatment, the application of microfluidics to detect metabolites in biological fluids is also discussed. Finally, the ultimate goal of personalised medicine is targeted therapy. One promising approach is RNAi technology which uses short nucleotides to disrupt cancer pathways. In this book, nanoparticle approaches to deliver these short nucleotides are discussed. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Condición: New.

Condición: As New. Unread book in perfect condition.

Hardback. Condición: New.

Condición: New. Editor(s): Shiddiky, Muhammad J. A.; Wee, Eugene J. H.; Rauf, Sakandar; Trau, Matt. Num Pages: 227 pages. BIC Classification: MBGR. Category: (P) Professional & Vocational. Dimension: 258 x 183 x 18. Weight in Grams: 556. . 2013. 1st Edition. Hardcover. . . . . Books ship from the US and Ireland.…

Gebunden. Condición: New. KlappentextrnrnIn recent years, thousands of cancer biomarkers have been discovered and described in scientific literature. The promise of personalised medicine, where diseases such as cancer are accurately diagnosed and treatments tailored spec.

Hardback. Condición: New. New Book, Direct from Publisher.

Hardback. Condición: New. New copy - Usually dispatched within 4 working days.

Buch. Condición: Neu. Neuware - In recent years, thousands of cancer biomarkers have been discovered and described in scientific literature. The promise of personalised medicine, where diseases such as cancer are accurately diagnosed and treatments tailored specifically for individuals, is becoming a reality. Significant advances in biomarker-based research methodologies such as Next Generation Sequencing (NGS) are at the cusp of ushering in a new era of personal medicine. However, unlike the spectacular advances in research technologies for disease biomarker discovery, biomarker-based technologies that can effectively be used in the clinic (or point-of-care) to enable personalised medicine are still lacking. In this book, we feature a selection of emerging technologies which are aimed at enabling clinical applications of personalised medicine. Each of the eight chapters is written by a leading group at the intersection of microfluidics, biology, and nanotechnology. For instance, to accelerate a major bottleneck in the development of clinically useful protein diagnostics, we discuss the application of yeast-derived single chain Fragment variable (scFv) antibody-like molecules as a potential low cost alternative to traditional antibody-based diagnostics. Circulating tumour cells (CTCs) are an emerging class of cancer biomarkers and a potential resource for understanding cancer progression; we explore various strategies combining microfluidics with nanotechnology for capturing CTCs. The book includes an evaluation of some current and emerging technologies for detecting clinical DNA methylation, another potential cancer biomarker. As personalised medicine may involve tracking a patient's response to treatment, the application of microfluidics to detect metabolites in biological fluids is also discussed. Finally, the ultimate goal of personalised medicine is targeted therapy. One promising approach is RNAi technology which uses short nucleotides to disrupt cancer pathways. In this book, nanoparticle approaches to deliver these short nucleotides are discussed.…

Hardback. Condición: New.

Hardcover. Condición: new. Hardcover. In recent years, thousands of cancer biomarkers have been discovered and described in scientific literature. The promise of personalised medicine, where diseases such as cancer are accurately diagnosed and treatments tailored specifically for individuals, is becoming a reality. Significant advances in biomarker-based research methodologies such as Next Generation Sequencing (NGS) are at the cusp of ushering in a new era of personal medicine. However, unlike the spectacular advances in research technologies for disease biomarker discovery, biomarker-based technologies that can effectively be used in the clinic (or point-of-care) to enable personalised medicine are still lacking. In this book, we feature a selection of emerging technologies which are aimed at enabling clinical applications of personalised medicine. Each of the eight chapters is written by a leading group at the intersection of microfluidics, biology, and nanotechnology.For instance, to accelerate a major bottleneck in the development of clinically useful protein diagnostics, we discuss the application of yeast-derived single chain Fragment variable (scFv) antibody-like molecules as a potential low cost alternative to traditional antibody-based diagnostics. Circulating tumour cells (CTCs) are an emerging class of cancer biomarkers and a potential resource for understanding cancer progression; we explore various strategies combining microfluidics with nanotechnology for capturing CTCs. The book includes an evaluation of some current and emerging technologies for detecting clinical DNA methylation, another potential cancer biomarker. As personalised medicine may involve tracking a patient's response to treatment, the application of microfluidics to detect metabolites in biological fluids is also discussed. Finally, the ultimate goal of personalised medicine is targeted therapy. One promising approach is RNAi technology which uses short nucleotides to disrupt cancer pathways. In this book, nanoparticle approaches to deliver these short nucleotides are discussed. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.…